期刊
VACCINE
卷 27, 期 23, 页码 3063-3071出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.03.018
关键词
Mycobacterium tuberculosis; Subunit vaccine; TLR agonists
资金
- NIH [N01-AI-25479, AI-044373, AI-067251]
We have developed the Mycobacterium tuberculosis (Mtb) fusion protein (11383), which contains the three Mtb proteins Rv1813, Rv3620 and Rv2608. We evaluated the immunogenicity and protective efficacy of ID83 in combination with several emulsion-formulated toll-like receptor agonists. The ID83 subunit vaccines containing synthetic TLR4 or TLR9 agonists generated a T helper-1 immune response and protected mice against challenge with Mtb regardless of route. The ID83 vaccine formulated with gardiquimod (a TLR7 agonist) also resulted in a protective response when administered intradermally, whereas the same vaccine given subcutaneously failed to provide protection. This highlights the need to explore different routes of immunization based on the adjuvant formulations used. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据